Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IL-17RA blockade by brodalumab hidradenitis suppurativa

ABSTRACT: IL-17RA blockade by brodalumab hidradenitis suppurativa

PROVIDER: PRJNA782312 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16992700_1.fastq.gz	Fastqsanger.gz
	SRR16992700_2.fastq.gz	Fastqsanger.gz
	SRR16992701_1.fastq.gz	Fastqsanger.gz
	SRR16992701_2.fastq.gz	Fastqsanger.gz
	SRR16992702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 150

Similar Datasets

Gene expression profiling of blood in hidradenitis suppurativa

Project description:To acquire a better understanding of the molecular pathogenesis of hidradenitis suppurativa (HS), we performed mRNA microarray studies to compare whole blood gene expression of HS patients to that of healthy normal subjects. No significant difference was observed in whole blood mRNA expression between HS patients and healthy normal control. Whole blood samples were collected from patients with hidradenitis (n=16) at baseline and healthy normal subjects (n=10) for RNA extraction and microarray analysis.

2016-03-11 | E-GEOD-79149 | biostudies-arrayexpress

Circulating LncRNAs Microarray Profiling in Hidradenitis suppurativa

Project description:Hidradenitis suppurativa (HS), also termed acne inversa, is a persistent inflammatory dermatological condition affecting approximately 1% of the global population, causing significant morbidity. The etiology of HS is not fully elucidated, but it is known that immune dysfunction plays a critical role. In our research to discern the role of non-coding RNA in HS, we initially conducted a comparative analysis of the most significantly altered long non-coding RNA (lncRNA) and mRNA expressions.

2024-01-24 | E-MTAB-13699 | biostudies-arrayexpress

IL-17RA blockade by brodalumab hidradenitis suppurativa

Project description:The goal of this study is to characterize the molecular response of HS patients to brodalumab therapy in skin and serum, and to identify biomarkers of treatment response. Ten participants that received 210 mg/1.5mL brodalumab subcutaneously at week 0, 1, 2, 4 and every 2 weeks after were included in this molecular profiling study (NCT03960268). RNA-sequencing of nonlesional, perilesional and lesional HS skin biopsies was assessed.

2022-04-01 | GSE189266 | GEO

Molecular profile of hidradenitis suppurativa

Project description:Hidradenitis Suppurativa molecular taxonomy and key signaling pathways were studied by whole transcriptome profiling. Dysregulated genes were detected by comparing lesional and non lesional skin obtained from female HS patients and matched healthy controls using the Agilent array platform

2019-09-10 | GSE137141 | GEO

RNA sequencing of skin punch biopsies of lesional and non-lesional skin from hidradenitis suppurativa patients

Project description:This study investigated the underlying inflammatory pathways and cell types in hidradenitis suppurativa using transcriptomic approaches with RNA sequencing of lesional and non-lesional skin biopsies from hidradenitis suppurativa patients.

2023-12-06 | GSE249027 | GEO

Transcriptome profiling for hidradenitis suppurativa

Project description:Hidradenitis Suppurativa (HS) is a debilitating chronic inflammatory disease characterized by chronic abscess formation and development of multiple draining sinus tracts in the groin, axillae, and perineum. Through the use of transcriptomic approaches, we characterize the inflammatory responses in HS in depth, revealing the cell types and immune responses involved.

2020-10-05 | GSE154773 | GEO

Baseline Clinical, Hormonal and Molecular Markers Associated with Clinical Response to IL-23 Antagonism in Hidradenitis Suppurativa

Project description:Background: Hidradenitis Suppurativa is a complex inflammatory disease in which predicting therapeutic response remains challenging. Clinical trials of IL-23 antagonism have shown high variability leading to abandonment of various clinical trials. IL-23 is known to interact with sex hormones in. monocytes, dendritic cells, and T cells. Relationships of IL-23 clinical response in HS to hormonal and molecular markers of inflammation has not been previously assessed. Objectives: To assess whether baseline clinical, hormonal, or molecular markers are associated with clinical response to IL-23 antagonism with Risankizumab in Hidradenitis Suppurativa. Methods: 26 individuals with Hurley Stage 2/3 disease were administered Risankizumab 150mg Week 0,4,12. Baseline sex hormones and skin biopsies were taken. Clinical response at Week 16 assessed by the HiSCR, and differences between responders and non-responders assessed. Results: Clinical response to IL-23 antagonism was associated with male gender, elevated total serum testosterone, and decreased levels of FSH. nCounter gene expression identified consistent differential expressed genes to previously published RNAseq datasets. Stratification by clinical responders/non responders identified differentially expressed genes included TRAT1, TPSAB1/2, LTA, IL17A, CXCR1 as well as hormonally responsive genes including PLPP4 and MAPK10. Immunohistochemistry identified elevated numbers of CD11c, IL-17A and IL-17F positive cells compared to non-responders. CD11c+ cells significantly correlated with serum levels of total testosterone and inversely correlated with serum FSH.

2022-10-05 | GSE214820 | GEO

Transcriptome profiling for hidradenitis suppurativa

Project description:Transcriptome profiling for hidradenitis suppurativa

| PRJNA647407 | ENA

Molecular profile of hidradenitis suppurativa

Project description:Molecular profile of hidradenitis suppurativa

| PRJNA564628 | ENA

Molecular profile of apocrine glands in hidradenitis suppurativa

Project description:Molecular taxonomy and key signaling pathways of apocrine glands of patients with hidradenitis suppurativa were studied by whole transcriptome profiling. Dysregulated genes were detected by comparing lesional and non lesional skin obtained from male and female HS patients using the Agilent array platform.

2020-02-06 | GSE144801 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data